EWTX

Edgewise Therapeutics Inc

EWTX, USA

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

https://edgewisetx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EWTX
stock
EWTX

Edgewise Therapeutics (NASDAQ:EWTX) Trading 4% Higher - Still a Buy? MarketBeat

Read more →
EWTX
stock
EWTX

Braidwell LP Raises Position in Edgewise Therapeutics, Inc. $EWTX MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$38.1667

Analyst Picks

Strong Buy

5

Buy

3

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.46

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-7.28 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-6.97 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.04

Low 1

High 0.3

Investors

* Institutions hold a combined 105.73% of the total shares of Edgewise Therapeutics Inc

1.

Orbimed Advisors, LLC

(14.731%)

since

2025/06/30

2.

RA Capital Management, LLC

(9.4001%)

since

2025/06/30

3.

Baker Bros Advisors LP

(6.9352%)

since

2025/06/30

4.

BlackRock Inc

(6.4369%)

since

2025/06/30

5.

Paradigm Biocapital Advisors LP

(5.8307%)

since

2025/06/30

6.

HHG PLC

(5.2241%)

since

2025/06/30

7.

Novo A/S

(5.0785%)

since

2025/06/30

8.

BRAIDWELL LP

(4.9464%)

since

2025/06/30

9.

Vanguard Group Inc

(4.5958%)

since

2025/06/30

10.

Perceptive Advisors LLC

(4.4045%)

since

2025/06/30

11.

Cormorant Asset Management, LLC

(4.0362%)

since

2025/06/30

12.

Siren, L.L.C.

(2.9999%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(2.6801%)

since

2025/07/31

14.

Bellevue Group AG

(2.6351%)

since

2025/06/30

15.

Driehaus Capital Management LLC

(1.9951%)

since

2025/06/30

16.

Deerfield Management Co

(1.9624%)

since

2025/06/30

17.

Geode Capital Management, LLC

(1.706%)

since

2025/06/30

18.

State Street Corp

(1.6911%)

since

2025/06/30

19.

iShares Russell 2000 ETF

(1.6742%)

since

2025/08/31

20.

MPM Oncology Impact Management LP

(1.6334%)

since

2025/06/30

21.

First Light Asset Management, LLC

(1.627%)

since

2025/06/30

22.

BB Biotech AG Ord

(1.3564%)

since

2024/12/31

23.

Artisan Partners Limited Partnership

(1.3091%)

since

2025/06/30

24.

Polar Capital Biotech S Inc

(0.9255%)

since

2025/07/31

25.

Artisan Non-U.S. Small-Mid Growth Comp

(0.8678%)

since

2025/06/30

26.

Artisan International Small-Mid Investor

(0.8678%)

since

2025/06/30

27.

Janus Henderson Global Life Sciences

(0.7956%)

since

2025/06/30

28.

Janus Henderson Global Life Sciences D

(0.7956%)

since

2025/06/30

29.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7117%)

since

2025/07/31

30.

Fidelity Small Cap Index

(0.695%)

since

2025/06/30

31.

Janus Global Life Science AUSD

(0.6553%)

since

2025/06/30

32.

Janus Henderson Glb Life Scn I2 USD

(0.649%)

since

2025/07/31

33.

iShares Russell 2000 Growth ETF

(0.6143%)

since

2025/08/31

34.

American Century Small Cap Growth Inv

(0.5786%)

since

2025/06/30

35.

American Century U.S. Small Cap Growth

(0.5786%)

since

2025/06/30

36.

Eventide Healthcare & Life Sciences I

(0.5395%)

since

2025/06/30

37.

iShares Biotechnology ETF

(0.436%)

since

2025/08/31

38.

Victory Pioneer Select Mid Cap Growth A

(0.3908%)

since

2025/07/31

39.

Janus Henderson Triton D

(0.3712%)

since

2025/06/30

40.

Janus Henderson US SMID Cap Growth

(0.3712%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.39

EPS Estimate

-0.4009

EPS Difference

0.0109

Surprise Percent

2.7189%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.